France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

ever neuro pharma gmbh - chlorhydrate d'apomorphine hémihydraté - solution - 5 mg - composition pour 1 ml de solution > chlorhydrate d'apomorphine hémihydraté : 5 mg - antiparkinsoniens dopaminergiques

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

as kalceks - chlorhydrate d'apomorphine hémihydraté - solution - 5 mg - composition pour 1 ml de solution > chlorhydrate d'apomorphine hémihydraté : 5 mg - antiparkinsonien dopaminergique, agents dopaminergiques, agonistes dopaminergiques

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ever neuro pharma gmbh - chlorhydrate d'apomorphine 5 mg/ml - solution pour perfusion - 5 mg/ml - chlorhydrate d'apomorphine 5 mg/ml - apomorphine

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ever neuro pharma gmbh - chlorhydrate d'apomorphine 10 mg - solution injectable en cartouche - 10 mg/ml - chlorhydrate d'apomorphine 10 mg/ml - apomorphine

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dechra regulatory b.v. - chlorhydrate d'apomorphine 3 mg/ml - eq. apomorphine 2,56 mg/ml - solution injectable - 3 mg/ml - chlorhydrate d'apomorphine 3 mg/ml - apomorphine - chien

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

domes pharma - chlorhydrate d'apomorphine 1,17 mg/ml - eq. apomorphine 1 mg/ml - solution injectable - 1 mg/ml - chlorhydrate d'apomorphine 1.17 mg/ml - apomorphine - chien

Union européenne - français - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Union européenne - français - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabète sucré, type 2 - les médicaments utilisés dans le diabète - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 et 5. 1 pour les données disponibles sur différentes combinaisons).

France - français - ANSES (Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail)

dechra regulatory b.v. - apomorphine (sous forme de chlorhydrate hémihydraté) - solution injectable